Ignite Creation Date:
2025-12-25 @ 3:55 AM
Ignite Modification Date:
2026-03-13 @ 3:47 PM
Study NCT ID:
NCT04151602
Status:
COMPLETED
Last Update Posted:
2025-04-03
First Post:
2019-11-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Transmission of Tuberculosis Among Illicit Drug Use Linkages
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D014376', 'term': 'Tuberculosis'}], 'ancestors': [{'id': 'D009164', 'term': 'Mycobacterium Infections'}, {'id': 'D000193', 'term': 'Actinomycetales Infections'}, {'id': 'D016908', 'term': 'Gram-Positive Bacterial Infections'}, {'id': 'D001424', 'term': 'Bacterial Infections'}, {'id': 'D001423', 'term': 'Bacterial Infections and Mycoses'}, {'id': 'D007239', 'term': 'Infections'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2023-09-21', 'size': 517930, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_000.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2025-03-31T17:14', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'bioSpec': {'retention': 'SAMPLES_WITHOUT_DNA', 'description': 'Sputum, exhaled bio-aerosols'}, 'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'CASE_CONTROL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 802}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-04-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-04', 'completionDateStruct': {'date': '2024-08-22', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2025-04-02', 'studyFirstSubmitDate': '2019-11-01', 'studyFirstSubmitQcDate': '2019-11-04', 'lastUpdatePostDateStruct': {'date': '2025-04-03', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2019-11-05', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-10-26', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'TB disease prevalence', 'timeFrame': 'At baseline', 'description': 'Percentage of persons with TB disease based on results from Xpert Ultra and sputum culture'}, {'measure': 'Incipient TB prevalence', 'timeFrame': 'At baseline', 'description': 'Percentage of persons with incipient TB based on host RNA signature'}, {'measure': 'Proportion of active TB cases resulting from recent transmission within this network of PWUD', 'timeFrame': 'At baseline', 'description': 'Proportion of linked TB cases based on whole genome sequencing of the mycobacterium tuberculosis (Mtb) isolate and overlaying social epidemiological ties'}, {'measure': 'Quantity of aerosolized Mtb in exhaled breath: amount of aerosolized Mtb exhaled in one hour', 'timeFrame': 'One hour', 'description': 'The amount of aerosolized Mtb exhaled in one hour in a specialized bio-aerosol capturing booth'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Tuberculosis', 'Illicit Drug Use']}, 'descriptionModule': {'briefSummary': 'Tuberculosis (TB) is the leading infectious disease killer globally and leading cause of death in persons with HIV. The most effective way to reduce TB incidence and mortality is to interrupt transmission. This requires finding and treating individuals with TB disease early, including those with subclinical disease. Molecular epidemiologic studies and mathematical models have shown that the primary approach to case finding-household contact tracing-identifies only 8-19% of transmissions in high TB and TB/HIV burden settings. Thus there is a clear need to identify new groups and settings where TB transmission occurs. Spatial clustering of individuals with higher rates of progression from infection to disease, such as those with HIV and malnourishment, can also form transmission hotspots. Illicit drug (i.e., methamphetamines, crack/cocaine, opiates) users have higher TB infection prevalence and disease incidence compared to non-users, likely due to significant within-group transmission and/or clustered vulnerability. Increased transmission among people who use illicit drugs (PWUD) could result from creation of more efficient TB transmitters, increased close contact among transmitters, increased rates of primary progression from infection to disease among contacts, or a combination. Interrogation of illicit drug user networks for TB transmission, therefore, holds great potential as a target for early case identification and linkage to treatment, with potential benefit for halting transmission to the broader population.', 'detailedDescription': "A cross-sectional, observational study design using respondent driven sampling (RDS) will be used for this research study.\n\nIn Aim 1, individuals will be recruited who currently use meth and/or Mandrax to assess TB exposure, incipient TB prevalence, and TB disease prevalence in the network. RDS will be used to seek out 750 meth/Mandrax users. Initial seeds (N=4) will be individuals from the investigator's current R01, the Tuberculosis treatment outcomes and alcohol use study (TRUST) cohort who have had active pulmonary TB disease in the prior 1-2 years and report current meth/Mandrax use.\n\nFor Aim 2, individuals from Aim 1 identified to have possible TB disease will be screened and enrolled to estimate the proportion that reflect recent transmission via genotyping and social epidemiologic links.\n\nIn Aim 3, the investigators will examine physiologic factors that may make PWUD more efficient TB transmitters. 50 PWUD participants from Aim 2 will be recruited who have active, untreated pulmonary TB and 50 individuals with active, untreated pulmonary TB who do not use meth/Mandrax, matched on age and gender will be recruited"}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD', 'ADULT', 'OLDER_ADULT'], 'minimumAge': '15 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': '750 PWUD in the Western Cape, South Africa will be enrolled into Aim 1. An anticipated 45-75 will have active TB disease and enrolled into Aim 2 and Aim 3 Arm 1 of the study.\n\n50 people who do not smoke illicit drugs with active TB disease will be enrolled into Aim 3 Arm 2.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Participants must be/have the following general inclusion criteria:\n\n1. at least 15 years old\n2. resident of the study community\n3. intact mental status at enrollment (i.e., no acute intoxication)\n4. provide written, informed consent to participate in the study if ≥18 years or written assent and parental consent if \\<18 years.\n5. agree to comply with all study requirements, including provision of contact information and study appointments attendance\n\nAnd for Aim 1:\n\n1. self-reported meth or Mandrax use in the past month\n2. urine drug screen positive for meth and/or Mandrax\n3. all participants other than the seeds must also have evidence that they have been recruited by a peer (the coupon)\n\nFor Aim 2 participants must meet all general inclusion criteria and the inclusion criteria from Aim 1 (meth/Mandrax use) and:\n\n(1) Have evidence of active TB disease on Xpert Ultra from their Aim 1 visit testing or report a recent TB diagnosis (within the past month)\n\nFor Aim 3 Arm 1 participants must meet all general inclusion criteria and the criteria under Aim 1 and Aim 2 (active illicit drug use and active TB)\n\nAnd exclusion criteria:\n\n1. No current pregnancy by urine pregnancy test\n2. Not yet started on TB medication\n\nFor Aim 3 Arm 2 patients must meet all general inclusion criteria and the following inclusion criteria:\n\n1. Attend the Worcester Community Day Clinic, the Empilisweni Clinic, or any other clinic and live in the general Worcester area\n2. Have newly diagnosed TB\n\nAnd exclusion criteria:\n\n1. No self-reported drug use or evidence of drug use by urine test\n2. No current pregnancy by urine pregnancy test\n3. Not yet started TB medication\n\nGeneral exclusion criteria under all aims and arms of the study include:\n\n1. Current drug or alcohol intoxication\n2. Mental incapacitation to providing informed consent\n3. Not currently or previously enrolled in any prophylactic TB therapy studies\n\nParticipants may also be excluded from the study under discretion of the Principal Investigator if the PI believes participation in the study may prove harmful to the participant or the research staff.\n\nParticipants will be enrolled from the main cohort (n=750) (Aim 1) into the additional cohorts under Aims 2 and Aim 3 Arm 1. Aim 3 Arm 2 will be recruited external to the main cohort (Aim 1)'}, 'identificationModule': {'nctId': 'NCT04151602', 'acronym': 'TOTAL', 'briefTitle': 'Transmission of Tuberculosis Among Illicit Drug Use Linkages', 'organization': {'class': 'OTHER', 'fullName': 'Boston Medical Center'}, 'officialTitle': 'Transmission of Tuberculosis Among Illicit Drug Use Linkages', 'orgStudyIdInfo': {'id': 'H-38910'}, 'secondaryIdInfos': [{'id': '1R01AI147316-01', 'link': 'https://reporter.nih.gov/quickSearch/1R01AI147316-01', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'PWUD with active TB', 'description': 'People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with active TB disease', 'interventionNames': ['Behavioral: Smoked illicit drug use']}, {'label': 'PWUD with no active TB', 'description': 'People who use smoked illicit drugs (methamphetamine and/or methaqualone (mandrax)) with no active TB disease', 'interventionNames': ['Behavioral: Smoked illicit drug use']}, {'label': 'non-PWUD with active TB', 'description': 'People who do not use meth/mandrax who have active TB disease'}], 'interventions': [{'name': 'Smoked illicit drug use', 'type': 'BEHAVIORAL', 'description': 'The exposure of interest is current smoked illicit drug use, particularly methamphetamine and/or methaqualones', 'armGroupLabels': ['PWUD with active TB', 'PWUD with no active TB']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Worcester', 'country': 'South Africa', 'facility': 'Privately Rented Facility', 'geoPoint': {'lat': -33.64651, 'lon': 19.44852}}], 'overallOfficials': [{'name': 'Karen Jacobson, MD MPH', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Boston Medical Center/ BUMC'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boston Medical Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'University of Stellenbosch', 'class': 'OTHER'}, {'name': 'Desmond Tutu HIV Foundation', 'class': 'OTHER'}, {'name': 'Boston University', 'class': 'OTHER'}, {'name': 'Medical Research Council, South Africa', 'class': 'OTHER'}, {'name': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'class': 'NIH'}], 'responsibleParty': {'type': 'SPONSOR'}}}}